In a regulatory filing, Coupang disclosed that its director Benjamin Sun sold 373K shares of common stock on December 1st in a total transaction size of $7.47M.

General Motors' BrightDrop announced it had entered its first international market, Canada, adding DHL Express Canada to its customer portfolio. The company also announced production of the BrightDrop Zevo 600 electric delivery vans had begun at GM's CAMI Assembly plant in Ontario, making the facility Canada's first large-scale EV factory. BrightDrop offers a suite of products including the Zevo electric delivery vans, the Trace eCarts, and the BrightDrop Core software platform to reduce carbon emissions from last mile delivery while reducing urban congestion. The business launched in 2021 with a nearly $800M investment from its parent company GM to convert the CAMI Assembly plant to BrightDrop's high-volume EV production facility. Entering the Canadian market is BrightDrop's latest effort to address the $250B last-mile delivery industry, particularly as companies around the world set goals to electrify their fleets and optimize operations. DHL Express Canada plans to add its first BrightDrop Zevo electric delivery vans to its fleet early next year.

In an interview on CNBC's Mad money, Michael Skipworth said, "We've got plenty of inventory." He expects a favorable commodity backdrop for 2023 with strong comp growth. "We're set up for a 19th quarter of consecutive growth," he added.

LGI Homes "announced it closed 412 homes in November 2022. As of November 30, 2022, the company had 92 active selling communities."

Textron "announced that Bell Textron Inc., a Textron company, has been awarded the development contract for the U.S. Army's Future Long-Range Assault Aircraft program. The award is based on Bell's V-280 Valor tiltrotor that was developed and tested as part of the Joint Multi-Role Technology Demonstrator program that began in 2013. The V-280 progressed through design, manufacturing, and more than three years of rigorous flight testing that provided extensive data validating the technical and operational advantages of the aircraft for the long-range assault mission. The initial contract refines the weapon system design, sustainment, digital enterprise, manufacturing, systems integration, flight-testing, and airworthiness qualification."

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that positive results from a secondary analysis of a Phase 2 trial of MN-166 in alcohol use disorder were published in The American Journal of Drug and Alcohol Abuse. The clinical trial was a collaborative effort between MediciNova and Dr. Lara Ray, Professor, Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute at the University of California at Los Angeles and was funded by the National Institute on Drug Abuse. Topline results from a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in 52 non-treatment seeking individuals with AUD found that MN-166 reduced heavy drinking and attenuated neural cue-reactivity compared to placebo. Neural and peripheral inflammation has been implicated in the development and maintenance of AUD, as evidenced by increased inflammation in such individuals. A secondary analysis of this study was performed to determine if participants with elevated peripheral levels of proinflammatory proteins, specifically C-reactive protein, would show a greater benefit from MN-166 as assessed by clinical and biological outcomes.